RPID, US75340L1044

Rapid Micro Biosystems stock to join Merck after USD 0.75 deal

Published on 11/20/2026 at 00:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rapid Micro Biosystems stock is tied to Merck KGaA's proposed acquisition of the company. The deal is expected to close in December, subject to tender and other conditions.

Deal Terms And Next Steps

  • Merck KGaA has agreed to acquire all outstanding Rapid Micro Biosystems shares in an all-cash transaction.
  • The tender offer has not started, and completion remains subject to customary conditions.
  • Rapid Micro Biosystems would become part of Merck's Life Science business after closing.
RPID, US75340L1044, Illustration mit AI erstellt.

Rapid Micro Biosystems said on November 16 that it had signed a definitive agreement to be acquired by Merck KGaA in an all-cash transaction. Under the terms, Merck would acquire all outstanding shares at USD 0.75 each. The Rapid Micro Biosystems announcement said the transaction is expected to close in December 2026.

Tender Offer Still Ahead

The transaction remains subject to the successful completion of the tender offer, including a minimum tender condition, and other customary closing conditions. The tender offer has not yet commenced. Once completed, Rapid Micro Biosystems would become part of Merck's Life Science business.

The proposed deal would give Merck control of Rapid's Growth Direct platform, which automates microbial quality-control testing for pharmaceutical manufacturing. The transaction therefore links Rapid's specialized automation business with Merck's broader life-science portfolio while leaving completion risk with shareholders and the parties until the tender process and closing conditions are satisfied.

Automation For Pharmaceutical Quality Control

Rapid Micro Biosystems provides automation solutions for the manufacturing and release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates microbial quality-control workflows and is designed for large pharmaceutical manufacturing operations. The company is headquartered in Lexington, Massachusetts, with manufacturing in Lowell and additional locations in Switzerland, Germany, and the Netherlands.

Rapid Micro Biosystems At A Glance

  • Company: Rapid Micro Biosystems, Inc.
  • ISIN: US75340L1044
  • Ticker: RPID
  • Primary exchange: Nasdaq
  • Transaction: Proposed acquisition by Merck KGaA for USD 0.75 per share in cash
  • Expected closing: December 2026, subject to conditions

The US market backdrop is covered by the S&P 500 market page.

Find more news and analyses on Rapid Micro Biosystems stock.

Disclaimer...
en | US75340L1044 | RPID | boerse | 70538166 | bgmi